Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_DNA, RNA, RNAi, siRNA & mRNA

DTx Pharma

Attachments

2021: DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA Therapeutics
2021: The Series B financing was led by RA Capital Management with participation from Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, Logos Capital, Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures.
Created a platform called FALCON™ (Fatty Acid Ligand Conjugated OligoNucleotide) that promotes efficient non-toxic cellular uptake and enhanced systemic bioavailability.
DTx Pharma FALCON technology addresses the fundamental challenges associated with delivering RNA therapeutics by leveraging fatty acid receptors for cellular uptake and leveraging fatty acid albumin interactions to promote biodistribution.
San Diego, California